Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)
Income Statement
Others
Ratios

Nexalin Technology (NXL) Net Cash Flow Growth (1y) (2022 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -53.07%
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 17.60%
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -562.50%
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -283.58%
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -564.44%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 76.43%
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -31.84%
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -394.13%
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 57.36%
10 Nexalin Technology 11.19 Mn 8.48 Mn 13,133.00 1,063.37%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1,063.37%
Dec 31, 2025 -86.88%
Sep 30, 2025 103.00%
Jun 30, 2025 -1,698.83%
Mar 31, 2025 239.94%
Dec 31, 2024 125.31%
Sep 30, 2024 -4,174.46%
Jun 30, 2024 433.01%
Mar 31, 2024 -378.07%
Dec 31, 2023 124.14%
Sep 30, 2023 -98.29%
Jun 30, 2023 133.93%
Mar 31, 2023 106.01%
Dec 31, 2022 -272.54%